Dermapharm (DMP.F)

Executive Summary

Dermapharm Holding SE is a German specialty pharmaceutical company with a €2.3 billion market capitalization, specializing in branded generics, original branded products, and biosimilars, particularly in dermatology. Founded in 1991 and headquartered in Grünwald near Munich, the company operates an integrated business model encompassing in-house development, manufacturing, and a trained pharmaceutical sales force, complemented by a parallel import subsidiary. Listed on the Frankfurt Stock Exchange's Prime Standard, Dermapharm leverages German manufacturing excellence and regulatory expertise to maintain a competitive position in the European pharmaceutical market. With a portfolio of 10 commercial products, the company has demonstrated consistent execution and a strong presence in its niche, though growth is driven by product launches and regulatory milestones rather than blockbuster innovation.

Upcoming Catalysts (preview)

• Q4 2026EU approval of a new biosimilar (e.g., adalimumab) for dermatology indications70% success
• Q2 2027Launch of a branded generic in topical corticosteroids or antifungals80% success
• H1 2027Acquisition of a complementary specialty pharma asset to expand pipeline50% success